ICER Finds ‘Substantial Uncertainties’ in Lykos’ MDMA Trials Ahead of Adcomm

Due to concerns of study bias, the Institute for Clinical and Economic Review on Tuesday said in a draft report that it is unable to accurately assess the net benefit of Lykos Therapeutics’ investigational MDMA-assisted therapy in post-traumatic stress disorder.